433331-28-3

Basic information

• Product Name: Benzoic acid, 4-[[2-(phenylmethoxy)phenyl]methyl]-, methyl ester
• CAS NO: 433331-28-3
• Molecular Formula: C22H20O3
• Molecular Weight: 332.399
• Mol File: 433331-28-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[[2-(phenylmethoxy)phenyl]methyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[2-(phenylmethoxy)phenyl]methyl]-, methyl ester(433331-28-3)
• EPA Substance Registry System: Benzoic acid, 4-[[2-(phenylmethoxy)phenyl]methyl]-, methyl ester(433331-28-3)

Safety Data

• Hazardous Substances Data: 433331-28-3(Hazardous Substances Data)

Upstream product

• 433331-27-2 4-(2-hydroxybenzyl)benzoic acid methyl ester 
• 100-39-0 benzyl bromide 
• 1571-08-0 methyl 4-formylbenzoate 
• 328000-16-4 (2-(benzyloxy)phenyl)magnesium bromide 
• 31575-75-4 2-bromophenyl benzyl ether 
• 433331-26-1 4-[(2-Benzyloxyphenyl)hydroxymethyl]-benzoic Acid Methyl Ester 

Downstream Products

• 433331-29-4 4-(2-benzyloxybenzyl)benzyl alcohol 
• 433331-47-6 4-(2-benzyloxybenzyl)benzoic acid 
• 433331-27-2 4-(2-hydroxybenzyl)benzoic acid methyl ester 
• 433331-49-8 4-(2-hydroxybenzyl)benzamide 
• 433331-30-7 4-(2-benzyloxybenzyl)benzaldehyde 
• 433331-48-7 4-(2-benzyloxybenzyl)benzamide 
• 433331-32-9 ethyl (E)-3-[4-(2-benzyloxybenzyl)phenyl]acrylate 
• 433332-02-6 2-(4-carbamoylbenzyl)phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 875109-88-9 [2-(4-carboxybenzyl)phenyl]-2,3,4,5-tetra-O-benzyl-5a-carba-β-D-glucopyranoside 

Relevant articles and documents

NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF

The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted (lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.